GCCA
23.8.2021 13:02:11 CEST | Business Wire | Press release
The third annual GCCA “Concrete in Life” photography competition has today launched with a call for amateur and professional photographers from around the world to capture the role of concrete in their lives and its role in the sustainable world of tomorrow.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210823005132/en/
Concrete plays a key role in supporting society around the world. Its durability, strength, resilience and boundless versatility means it can be used for nearly any application, while its properties such as thermal mass, recyclability and carbon uptake make it the most sustainable building material.
Judges include Isabel Allen, Editor at Architecture Today, Gian Luca Barone from Zaha Hadid Architects and experts from the Global Cement and Concrete Association (GCCA). They will be looking for entries showing concrete contributing to their individual lives and wider society, and notably sustainable buildings and infrastructure, to inspire the public in the run up to COP26, as the GCCA prepares to announce its detailed roadmap to zero carbon concrete.
Contestants are invited to capture imagery in the following categories, which include a brand new Sustainable Concrete category:
- Urban design and use – images of the city landscapes and buildings around us, both well-known and hidden away
- Infrastructure – photographs of our infrastructure, in our cities and rural, above and below ground
- Concrete in daily life – the human side of concrete and how it’s used and interacted with daily
- Sustainable Concrete – how concrete is used in sustainable construction, buildings and infrastructure such as wind farms, dams, green overpasses, wildlife crossings, green buildings
The competition crown one winner for the professional and amateur brackets of each category as well as one overall winner for the “Best Concrete in Life” photo of the year from the eight finalists. Each category winner will receive $2,500 in prize money, while the overall winner will receive $10,000.
Thomas Guillot, GCCA Chief Executive, said: “Being the world’s most used human-made product, concrete provides the foundation for so many lives. The competition is designed to capture that importance and demonstrate its versatility throughout society. Entries to the first two ‘Concrete in Life’ competitions from both professionals and amateurs were exceptional and managed to capture concrete’s strength, durability and resilience, and we’re so excited to be launching the third annual competition. We look forward to receiving a wide array of unique and inspiring entries from all over the world.”
The annual competition by the GCCA attracts tens of thousands of entries from professional and amateur photographers and challenges participants to capture photos that highlight the beauty of concrete and the vital role it plays in our society.
To enter the competition, participants should post a picture that they’ve taken on Instagram or Twitter using the hashtags #ConcreteInLife2021, #UrbanConcrete, #ConcreteInfrastructure, #ConcreteInDailyLife, and #SustainableConcrete. They should also tag the GCCA – @the.gcca on Instagram or @theGCCA on Twitter.
Winners will also be invited to speak about their images with the GCCA, with their images shared on GCCA’s website and social media channels.
Judging the entries are:
- Gian Luca Barone, Senior Associate, Zaha Hadid Architects
- John Fairley, Design Director, Curious Productions
- Thomas Guillot, GCCA Chief Executive
- Isabel Allen, Editor, Architecture Today
The competition will run until October 22nd 2021, with the winners announced during January 2022. Full competition details can be found at https://gccassociation.org/concreteinlife2021/
-ends-
About the GCCA:
Launched in January 2018, the Global Cement and Concrete Association (GCCA) is dedicated to developing and strengthening the sector’s contribution to sustainable construction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210823005132/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
